Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darren Plant

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Pharmacogenetics and Genomics|March 6, 2009
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patientsJohn D Bowes, Catherine Potter, Laura J Gibbons, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
Rheumatology (Oxford, England)|June 30, 2023
A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measuresStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Lancet (London, England)|August 28, 2015
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Plos One|September 17, 2013
Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek populationMaria I Zervou, Efsevia Myrthianou, Irene Flouri, et al.
The Pharmacogenomics Journal|September 1, 2018
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisJonathan Massey, Darren Plant, Kimme Hyrich, et al.
Rheumatology (Oxford, England)|June 2, 2023
Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritisSizheng Steven Zhao, Kira Rogers, Lianne Kearsley-Fleet, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2020
Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic DrugsArianna Dagliati, Darren Plant, Nisha Nair, et al.
Annals of the Rheumatic Diseases|September 12, 2023
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritisChuan Fu Yap, Nisha Nair, Annick de Vries, et al.
Journal of Biomolecular Screening|October 6, 2006
High-throughput screening of RNA polymerase inhibitors using a fluorescent UTP analogJyothi Bhat, Rajendra Rane, Suresh M Solapure, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Pharmacogenetics and Genomics|March 6, 2009
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patientsJohn D Bowes, Catherine Potter, Laura J Gibbons, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
Rheumatology (Oxford, England)|June 30, 2023
A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measuresStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Lancet (London, England)|August 28, 2015
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Plos One|September 17, 2013
Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek populationMaria I Zervou, Efsevia Myrthianou, Irene Flouri, et al.
The Pharmacogenomics Journal|September 1, 2018
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisJonathan Massey, Darren Plant, Kimme Hyrich, et al.
Rheumatology (Oxford, England)|June 2, 2023
Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritisSizheng Steven Zhao, Kira Rogers, Lianne Kearsley-Fleet, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2020
Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic DrugsArianna Dagliati, Darren Plant, Nisha Nair, et al.
Annals of the Rheumatic Diseases|September 12, 2023
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritisChuan Fu Yap, Nisha Nair, Annick de Vries, et al.
Journal of Biomolecular Screening|October 6, 2006
High-throughput screening of RNA polymerase inhibitors using a fluorescent UTP analogJyothi Bhat, Rajendra Rane, Suresh M Solapure, et al.
Pageof 11